Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir

Phillip, Kathryn; Nair, Nisha; Samanta, Kamalika; Azevedo, Jose F; Brown, Grant; Petersen, Christine A.; Gomes-Solecki, Maria

doi:10.1016/j.vaccine.2021.06.025

Cited by 3 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…burgdorferi s.s. OspA after oral vaccination of lactating Mu. musculus mice ( Phillip et al, 2021 ).…”

Section: Empirical Evidence For Impact Of Rodent-targeted Approaches ...mentioning

confidence: 99%

“…scapularis in the environment, reduce human bites by this tick, and ultimately prevent cases of human illness caused by Ix. scapularis -associated pathogens ( Dolan et al, 2017 ; Schulze et al, 2017 ; Keesing and Ostfeld, 2018 ; Williams et al, 2018a , 2018b , 2020 ; Buchtal et al, 2019 ; Jordan and Schulze, 2019 , 2020 ; Machtinger and Li, 2019 ; Brown et al, 2020 ; Carrera-Pineyro et al, 2020 ; Pelletier et al, 2020 , 2022 ; Poché et al, 2020 , 2021 ; Stafford et al, 2020 ; Hinckley et al, 2021 ; Mandli et al, 2021 ; Phillip et al, 2021 ; van Oosterwijk and Wikel, 2021 ; Keesing et al, 2022 ; Linske et al, 2022 ). These recently published studies, which include large scale intervention trials that involved rodent-targeted acaricide and assessed human-based outcomes, sets the stage for a fresh assessment of the future of rodent-targeted tick and pathogen control methods.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rodent-targeted approaches to reduce acarological risk of human exposure to pathogen-infected Ixodes ticks

Eisen

2023

Ticks and Tick-borne Diseases

View full text Add to dashboard Cite

“…burgdorferi s.s. OspA after oral vaccination of lactating Mu. musculus mice ( Phillip et al, 2021 ).…”

Section: Empirical Evidence For Impact Of Rodent-targeted Approaches ...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rodent-targeted approaches to reduce acarological risk of human exposure to pathogen-infected Ixodes ticks

Eisen

2023

Ticks and Tick-borne Diseases

View full text Add to dashboard Cite

“…Neutralization antibody (nAb) assay: Briefly, blood was collected from groups of vaccinated mice the day before challenge (d117) for the 4-month challenge experiment, and on days 270 and 533 from groups of vaccinated mice that were not subjected to challenge for the 9 month and 18 month experiments, respectively. Neutralization of multi-strain cultures of B. burgdorferi by fresh serum was performed as described 15 . Briefly, 8 µl of the bacterial culture was mixed with 4 µl of heat-inactivated mouse serum obtained from vaccinated and control mice and with 4 µl guinea pig complement (MP Biomedicals™) in a 0.2 ml sterile PCR tube (VWR, LLC Radnor, PA).…”

Section: Immunization Immunogenicity and Vaccine Efficacy Analysismentioning

confidence: 99%

“…Enzyme-linked immunosorbent assay (ELISA): Anti-OspA and anti-B. burgdorferi VlsE antibody was determined by ELISA 15 . Briefly, 5-10µg/ml of purified recombinant OspA or VlsE were coated on flat-bottom ELISA plates (Thermo Fisher Nunc MaxiSorp) and incubated at 4°C overnight.…”

Section: Immunization Immunogenicity and Vaccine Efficacy Analysismentioning

confidence: 99%

A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice

Gomes-Solecki,

Gingerich,

Nair

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Lyme disease (LD) is the most prevalent vector borne disease in North America and Europe and its geographic range continues to expand. Strategies for disease control are necessary to effectively reduce incidence of LD including development of safe vaccines for human use. Parainfluenza virus 5 (PIV5) vector has an excellent safety record in animals and PIV5- vectored COVID-19 and RSV vaccines are currently under clinical development. We constructed PIV5-vectored LD vaccine candidates expressing OspA from B. burgdorferi sensu stricto (OspAB31) and a chimeric protein containing sequences from B. burgdorferi and B. afzelii (OspABPBPk). Immunogenicity and vaccine efficacy were analyzed in C3H-HeN mice after prime-boost intranasal (IN) vaccination with PIV5-OspAB31 and PIV5-OspABPBPk, subcutaneous (SC) vaccination with rOspAB31+Alum as well as the respective controls. Mice vaccinated with either PIV5-AB31 or PIV5-ABPBPk intranasally had high endpoint titers of serum antibody against OspA antigen beyond 1 year post vaccination, similar to levels detected in mice vaccinated SC with rOspAB31. Flowcytometric analysis of spleen cells at 9-months post-immunization demonstrated that immunization with the intranasal PIV5 vaccine candidates led to an overall increase in the number of memory B cells, cytotoxic T and cytotoxic effector T cells compared to SC groups. Borreliacidal activity measured by neutralization assay was maintained up to 18 months post-immunization, with the response greater in intranasal PIV5-delivered OspA vaccines, than that induced by SC rOspAB31. Challenge with infected ticks (10-19 strains of B. burgdorferi) performed at 4-, 9- or 15-months post-immunization showed increased breakthrough infections in mice vaccinated with SC rOspAB31 compared to IN PIV5-AB31 or IN PIV5-ABPBPk at 9- and 15-months, as determined by qPCR of B. burgdorferi in tissues, culture of B. burgdorferi from tissues, and antibodies against B. burgdorferi protein VIsE. These data demonstrate that intranasal PIV5-based immunization is superior to parenteral immunization with the same recombinant protein and provides long-lasting protection (> 1 year) against Lyme disease.

show abstract

Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year

Gingerich,

Nair,

Azevedo

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

Strategies for disease control are necessary to reduce incidence of Lyme Disease (LD) including development of safe vaccines for human use. Parainfluenza virus 5 (PIV5) vector has an excellent safety record in animals and PIV5-vectored vaccines are currently under clinical development. We constructed PIV5-vectored LD vaccine candidates expressing OspA from B. burgdorferi (OspAB31) and a chimeric protein containing sequences from B. burgdorferi and B. afzelii (OspABPBPk). Immunogenicity and vaccine efficacy were analyzed in C3H-HeN mice after prime-boost intranasal vaccination with live PIV5-OspAB31 or PIV5-OspABPBPk, subcutaneous (s.c.) vaccination with rOspAB31+Alum, and the respective controls. Mice vaccinated intranasally with live PIV5-AB31 or PIV5-ABPBPk had higher endpoint titers of serum antibody against OspAB31 at 6- and 12- months post vaccination, compared to mice vaccinated s.c. with rOspAB31. Neutralization activity of antibody was maintained up to 18-months post-immunization, with the response greater in live PIV5-delivered OspA vaccines, than that induced by s.c. rOspAB31. Challenge with infected ticks carrying 10-19 strains of B. burgdorferi performed at 4-, 9- or 15-months post-immunization showed increased breakthrough infections in mice vaccinated with s.c. rOspAB31 compared to intranasal PIV5-AB31 or PIV5-ABPBPk at 9- and 15-months, as determined by quantification of serologic antibodies to B. burgdorferi proteins as well as flaB DNA in tissues, and by visualization of motile B. burgdorferi in culture of tissues under dark field microscope. These findings indicate that immunization of mice with PIV5 delivered OspA generates immune responses that produce longer-lasting protection ( > 1 year) against tick-transmitted B. burgdorferi than a parenteral recombinant OspA vaccine.

show abstract

Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir

Cited by 3 publications

References 33 publications

Rodent-targeted approaches to reduce acarological risk of human exposure to pathogen-infected Ixodes ticks

Rodent-targeted approaches to reduce acarological risk of human exposure to pathogen-infected Ixodes ticks

A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice

Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year

Contact Info

Product

Resources

About